Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gelesis Closes $22M Equity Financing

By Drug Discovery Trends Editor | March 27, 2015

Gelesis, a clinical stage biotechnology company focused on the development of first-in-class products to induce weight loss and improve glycemic control, announced today that it closed an equity financing of shares of convertible preferred stock for gross proceeds of approximately $22 million, including the conversion of approximately $4 million of outstanding convertible promissory notes. Proceeds from the financing will be used to support the continued clinical development of its lead product, Gelesis100, as well as advancing its pipeline product, Gelesis 200, into the clinic.
 
“We’re pleased to receive this new round of financing to advance our products towards commercialization,”  said Yishai Zohar, Founder and Chief Executive Officer of Gelesis, “We appreciate the support from our new and existing investors in our mission to address the growing obesity and diabetes epidemics.”
 
In the first quarter, Gelesis added three leading experts in the treatment of obesity and its related comorbidities to its Scientific Advisory Board (SAB): Louis J. Aronne, MD, FACP, the Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College, Ken Fujioka, MD, Director of the Nutrition and Metabolic Research Center and the Center for Weight Management at the Scripps Clinic, and Angelo Tremblay, PhD, Professor in the Department of Social and Preventive Medicine at Laval University in Quebec City.
 
Gelesis also announced the appointment of two new directors, Meghan Fitzgerald and Robert Forrester, who bring additional commercialization and finance expertise to its Board. Ms. Fitzgerald is the EVP of Strategy, M&A, and Health Policy and an Executive Committee Member at Cardinal Health, a Fortune 22 company. She has previously held senior positions at Medco Health Solutions, Inc., Pfizer Global Pharmaceuticals, Merck and Sanofi. Mr. Forrester is the CEO of Verastem (NASDAQ: VSTM), and brings to the board 14 years of experience as CEO, COO, and CFO at both private and public life sciences companies, including Forma Therapeutics, CombinatoRx and Coley (acquired by Pfizer). 
 
Source: Gelesis100

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE